The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SLNO | -19.99% | -1.74% | -0.35% | -87% |
| S&P | +15.57% | +80.16% | +12.49% | +237% |
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
Soleno just turned profitable for the first time—right as a major fund made its move.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $91.73M | 0.0% |
| Gross Profit | $90.87M | 18165.0% |
| Gross Margin | 99.06% | 0.0% |
| Market Cap | $2.49B | 28.3% |
| Market Cap / Employee | $13.66M | 0.0% |
| Employees | 182 | 97.8% |
| Net Income | $42.94M | 176.7% |
| EBITDA | $40.94M | 170.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $70.11M | -20.3% |
| Accounts Receivable | $28.21M | 0.0% |
| Inventory | 15 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $51.83M | -0.9% |
| Short Term Debt | $726.00K | 38.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 4.58% | 73.3% |
| Return On Invested Capital | -108.51% | 29.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $48.65M | 302.7% |
| Operating Free Cash Flow | $48.70M | 303.0% |
| Metric | Q4 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 207.72 | - | |||
| Price to Book | 13.32 | 17.50 | 14.20 | 5.03 | -27.90% |
| Price to Sales | 129.51 | 37.63 | 13.21 | - | |
| Price to Tangible Book Value | 13.70 | 17.99 | 14.55 | 5.08 | -29.12% |
| Price to Free Cash Flow TTM | 53.91 | - | |||
| Enterprise Value to EBITDA | -72.44 | -811.75 | 140.67 | 55.27 | -285.58% |
| Free Cash Flow Yield | 1.9% | - | |||
| Return on Equity | -105.5% | -69.5% | -20.7% | 5.9% | -106.74% |
| Total Debt | $52.79M | $52.77M | $52.66M | $52.55M | -0.52% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
